403 related articles for article (PubMed ID: 33140187)
21. Germline and Tumor Sequencing as a Diagnostic Tool To Resolve Suspected Lynch Syndrome.
Pope BJ; Clendenning M; Rosty C; Mahmood K; Georgeson P; Joo JE; Walker R; Hutchinson RA; Jayasekara H; Joseland S; Como J; Preston S; Spurdle AB; Macrae FA; Win AK; Hopper JL; Jenkins MA; Winship IM; Buchanan DD
J Mol Diagn; 2021 Mar; 23(3):358-371. PubMed ID: 33383211
[TBL] [Abstract][Full Text] [Related]
22. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.
Haraldsdottir S; Hampel H; Tomsic J; Frankel WL; Pearlman R; de la Chapelle A; Pritchard CC
Gastroenterology; 2014 Dec; 147(6):1308-1316.e1. PubMed ID: 25194673
[TBL] [Abstract][Full Text] [Related]
23. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
Colle R; Lonardi S; Cachanado M; Overman MJ; Elez E; Fakih M; Corti F; Jayachandran P; Svrcek M; Dardenne A; Cervantes B; Duval A; Cohen R; Pietrantonio F; André T
Oncologist; 2023 Sep; 28(9):771-779. PubMed ID: 37023721
[TBL] [Abstract][Full Text] [Related]
24. The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers.
Liu GC; Liu RY; Yan JP; An X; Jiang W; Ling YH; Chen JW; Bei JX; Zuo XY; Cai MY; Liu ZX; Zuo ZX; Liu JH; Pan ZZ; Ding PR
J Natl Cancer Inst; 2018 Sep; 110(9):975-984. PubMed ID: 29471527
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
26. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR
Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042
[TBL] [Abstract][Full Text] [Related]
27. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
Carethers JM; Stoffel EM
World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
[TBL] [Abstract][Full Text] [Related]
28. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
[TBL] [Abstract][Full Text] [Related]
29. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
[TBL] [Abstract][Full Text] [Related]
30. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
[TBL] [Abstract][Full Text] [Related]
31. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
32. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.
Wang T; Lee LH; Vyas M; Zhang L; Ganesh K; Firat C; Segal NH; Desai A; Hechtman JF; Ntiamoah P; Weiser MR; Markowitz AJ; Vakiani E; Klimstra DS; Stadler ZK; Shia J
Mod Pathol; 2019 Oct; 32(10):1551-1562. PubMed ID: 31175329
[TBL] [Abstract][Full Text] [Related]
33. Targeted gene sequencing of Lynch syndrome-related and sporadic endometrial carcinomas.
Libera L; Craparotta I; Sahnane N; Chiaravalli AM; Mannarino L; Cerutti R; Riva C; Marchini S; Furlan D
Hum Pathol; 2018 Nov; 81():235-244. PubMed ID: 30420047
[TBL] [Abstract][Full Text] [Related]
34. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
[TBL] [Abstract][Full Text] [Related]
35. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.
Ladomersky E; Zhai L; Lenzen A; Lauing KL; Qian J; Scholtens DM; Gritsina G; Sun X; Liu Y; Yu F; Gong W; Liu Y; Jiang B; Tang T; Patel R; Platanias LC; James CD; Stupp R; Lukas RV; Binder DC; Wainwright DA
Clin Cancer Res; 2018 Jun; 24(11):2559-2573. PubMed ID: 29500275
[No Abstract] [Full Text] [Related]
36. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
[TBL] [Abstract][Full Text] [Related]
37. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
[TBL] [Abstract][Full Text] [Related]
38. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
[TBL] [Abstract][Full Text] [Related]
39. Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature.
Chinczewski L; Feldhaus FW; Schmitt W; Braicu I; Roser E; Sehouli J
Anticancer Res; 2023 Apr; 43(4):1655-1662. PubMed ID: 36974818
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
